Skip to main content
Top
Published in: Cancer Causes & Control 11/2011

01-11-2011 | Original paper

Regular aspirin use and breast cancer risk in US Black Women

Authors: Jaclyn L. F. Bosco, Julie R. Palmer, Deborah A. Boggs, Elizabeth E. Hatch, Lynn Rosenberg

Published in: Cancer Causes & Control | Issue 11/2011

Login to get access

Abstract

Background

Epidemiologic studies have yet to provide consistent evidence to support a protective effect of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) on the incidence of breast cancer.

Objective

We evaluated the relations of current use of aspirin, non-aspirin NSAIDs, and acetaminophen with breast cancer incidence in the Black Women’s Health Study.

Methods

Biennial follow-up of 59,000 study participants began in 1995. During 558,600 person-years of follow-up through 2007, 1,275 breast cancer cases were identified. Using Cox proportional hazards regression, we estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) for associations of current and former use of aspirin, other NSAIDs, and acetaminophen with incident breast cancer.

Results

After adjustment for age, education, body mass index at age 18, physical activity, female hormone use, current smoking, and other NSAID use, the IRRs were 0.79 (95% CI = 0.66, 0.95) for current aspirin use and 0.68 (95% CI = 0.50, 0.92) for ≥5 years of aspirin use. Similar associations were observed for acetaminophen use.

Conclusions

Both aspirin and acetaminophen use were inversely associated with breast cancer incidence in the present study. Reasons for the association with acetaminophen use are unclear, given that acetaminophen has very weak anti-inflammatory effects.
Literature
1.
go back to reference Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326–2333PubMedCrossRef Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326–2333PubMedCrossRef
2.
go back to reference Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358PubMedCrossRef Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358PubMedCrossRef
3.
go back to reference Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMed Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMed
4.
go back to reference Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303–309PubMedCrossRef Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303–309PubMedCrossRef
5.
go back to reference Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871–888PubMedCrossRef Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871–888PubMedCrossRef
7.
go back to reference The Endogenous Hormones Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616 The Endogenous Hormones Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616
8.
go back to reference Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460PubMedCrossRef Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460PubMedCrossRef
9.
go back to reference Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563–2570PubMedCrossRef Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563–2570PubMedCrossRef
10.
go back to reference Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100:1420–1423PubMedCrossRef Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100:1420–1423PubMedCrossRef
11.
go back to reference Harris RE, Namboodiri KK, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case–control study. Prev Med 24:119–120PubMedCrossRef Harris RE, Namboodiri KK, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case–control study. Prev Med 24:119–120PubMedCrossRef
12.
go back to reference Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMed Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMed
13.
go back to reference Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11:1586–1591 Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11:1586–1591
14.
go back to reference Ready A, Velicer C, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533–543PubMedCrossRef Ready A, Velicer C, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533–543PubMedCrossRef
15.
go back to reference Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14:261–264CrossRef Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14:261–264CrossRef
16.
go back to reference Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988–993PubMedCrossRef Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988–993PubMedCrossRef
17.
go back to reference Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169:115–121PubMedCrossRef Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169:115–121PubMedCrossRef
18.
go back to reference Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812PubMedCrossRef Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812PubMedCrossRef
19.
go back to reference Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158PubMedCrossRef Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158PubMedCrossRef
20.
go back to reference Gierach G, Lacey J, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38PubMedCrossRef Gierach G, Lacey J, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38PubMedCrossRef
21.
go back to reference Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRef Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRef
22.
go back to reference Zhang SM, Cook NR, Manson JE, Lee I-M, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98:989–991PubMedCrossRef Zhang SM, Cook NR, Manson JE, Lee I-M, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98:989–991PubMedCrossRef
23.
go back to reference Moorman P, Grubber J, Millikan R, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915–922PubMedCrossRef Moorman P, Grubber J, Millikan R, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915–922PubMedCrossRef
24.
go back to reference Palmer JR, Rao SR, Adams-Campbell LL, Rosenberg L (2001) Height and breast cancer risk: results from the Black Women’s Health Study (United States). Cancer Causes Control 12:343–348PubMedCrossRef Palmer JR, Rao SR, Adams-Campbell LL, Rosenberg L (2001) Height and breast cancer risk: results from the Black Women’s Health Study (United States). Cancer Causes Control 12:343–348PubMedCrossRef
25.
go back to reference Kelley KE, Kelley TP, Kaufman DW, Mitchell AA (2003) The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 12(S1):S168–S198 Kelley KE, Kelley TP, Kaufman DW, Mitchell AA (2003) The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 12(S1):S168–S198
26.
27.
go back to reference Monninkhof EM, Elias SG, Vlems FA et al (2007) Physical activity and breast cancer: a systematic review. Epidemiol 18:137–157CrossRef Monninkhof EM, Elias SG, Vlems FA et al (2007) Physical activity and breast cancer: a systematic review. Epidemiol 18:137–157CrossRef
28.
go back to reference Band PR, Le ND, Fang R, Deschamps M (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360:1044–1049PubMedCrossRef Band PR, Le ND, Fang R, Deschamps M (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360:1044–1049PubMedCrossRef
30.
go back to reference Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15:256–263PubMed Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15:256–263PubMed
31.
go back to reference Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36–47PubMed Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36–47PubMed
32.
go back to reference Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16PubMed Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16PubMed
33.
go back to reference Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34:187–220 Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34:187–220
34.
go back to reference Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York
35.
go back to reference Coogan PF, Rao SR, Rosenberg L et al (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29:72–76PubMedCrossRef Coogan PF, Rao SR, Rosenberg L et al (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29:72–76PubMedCrossRef
36.
go back to reference Brasky TM, Bonner MR, Moysich KB et al (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21:1503–1512PubMedCrossRef Brasky TM, Bonner MR, Moysich KB et al (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21:1503–1512PubMedCrossRef
37.
go back to reference Pedersen ATn, Ottesen B (2003) Issues to debate on the Women’s Health Initiative (WHI) study. Epidemiology or randomized clinical trial—time out for hormone replacement therapy studies? Hum Reprod 18:2241–2244PubMedCrossRef Pedersen ATn, Ottesen B (2003) Issues to debate on the Women’s Health Initiative (WHI) study. Epidemiology or randomized clinical trial—time out for hormone replacement therapy studies? Hum Reprod 18:2241–2244PubMedCrossRef
38.
go back to reference Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525–529PubMedCrossRef Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525–529PubMedCrossRef
39.
go back to reference Cronin-Fenton D, Pedersen L, Lash T, Friis S, Baron J, Sørensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case–control study. Breast Cancer Res 12:R15PubMedCrossRef Cronin-Fenton D, Pedersen L, Lash T, Friis S, Baron J, Sørensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case–control study. Breast Cancer Res 12:R15PubMedCrossRef
40.
go back to reference Harris R, Beebe-Donk J, Alshafie G (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRef Harris R, Beebe-Donk J, Alshafie G (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRef
41.
go back to reference Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159PubMedCrossRef Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159PubMedCrossRef
42.
go back to reference Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440PubMedCrossRef Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440PubMedCrossRef
43.
go back to reference Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211–215PubMedCrossRef Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211–215PubMedCrossRef
44.
go back to reference Friis S, Thomassen L, Sørensen HT et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Euro J Cancer Prev 17:88–96CrossRef Friis S, Thomassen L, Sørensen HT et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Euro J Cancer Prev 17:88–96CrossRef
45.
go back to reference Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomark Prev 19:1033–1041CrossRef Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomark Prev 19:1033–1041CrossRef
46.
go back to reference Graham GG, Scott KF (2005) Mechanism of action of paracetamol. Am J Therap 12:46–55CrossRef Graham GG, Scott KF (2005) Mechanism of action of paracetamol. Am J Therap 12:46–55CrossRef
47.
go back to reference Anderson BJ (2008) Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 18:915–921PubMedCrossRef Anderson BJ (2008) Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 18:915–921PubMedCrossRef
48.
go back to reference Aronoff DM, Oates JA, Boutaud O (2006) New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Therapeutics 79:9–19CrossRef Aronoff DM, Oates JA, Boutaud O (2006) New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Therapeutics 79:9–19CrossRef
49.
go back to reference Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMed Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327PubMed
50.
go back to reference Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 91:525–529 Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 91:525–529
51.
go back to reference Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiol 5:135–146CrossRef Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiol 5:135–146CrossRef
Metadata
Title
Regular aspirin use and breast cancer risk in US Black Women
Authors
Jaclyn L. F. Bosco
Julie R. Palmer
Deborah A. Boggs
Elizabeth E. Hatch
Lynn Rosenberg
Publication date
01-11-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9832-6

Other articles of this Issue 11/2011

Cancer Causes & Control 11/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine